Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge

Michael D. Alpert, Andrew R. Rahmberg, William Neidermyer, Sharon K. Ng, Angela Carville, Jeremy V. Camp, Robert L. Wilson, Michael Piatak, Keith G. Mansfield, Wenjun Li, Chris J Miller, Jeffrey D. Lifson, Pamela A. Kozlowski, David T. Evans

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Immunization of rhesus macaques with strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection elicits T-cell responses to multiple viral gene products and antibodies capable of neutralizing lab-adapted SIV, but not neutralization-resistant primary isolates of SIV. In an effort to improve upon the antibody responses, we immunized rhesus macaques with three strains of single-cycle SIV (scSIV) that express envelope glycoproteins modified to lack structural features thought to interfere with the development of neutralizing antibodies. These envelope-modified strains of scSIV lacked either five potential N-linked glycosylation sites in gp120, three potential N-linked glycosylation sites in gp41, or 100 amino acids in the V1V2 region of gp120. Three doses consisting of a mixture of the three envelope-modified strains of scSIV were administered on weeks 0, 6, and 12, followed by two booster inoculations with vesicular stomatitis virus (VSV) G trans-complemented scSIV on weeks 18 and 24. Although this immunization regimen did not elicit antibodies capable of detectably neutralizing SIV mac239 or SIVmac251UCD, neutralizing antibody titers to the envelope-modified strains were selectively enhanced. Virus-specific antibodies and T cells were observed in the vaginal mucosa. After 20 weeks of repeated, low-dose vaginal challenge with SIVmac251 UCD, six of eight immunized animals versus six of six naïve controls became infected. Although immunization did not significantly reduce the likelihood of acquiring immunodeficiency virus infection, statistically significant reductions in peak and set point viral loads were observed in the immunized animals relative to the naïve control animals.

Original languageEnglish (US)
Pages (from-to)10748-10764
Number of pages17
JournalJournal of Virology
Volume84
Issue number20
DOIs
StatePublished - Oct 2010

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
Antibody Formation
Immunization
antibodies
neutralizing antibodies
dosage
Neutralizing Antibodies
Macaca mulatta
Glycosylation
immunization
glycosylation
neutralization
Viral Antibodies
Viruses
T-Lymphocytes
T-lymphocytes
Vesicular Stomatitis
vaginal mucosa
Antibodies

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. / Alpert, Michael D.; Rahmberg, Andrew R.; Neidermyer, William; Ng, Sharon K.; Carville, Angela; Camp, Jeremy V.; Wilson, Robert L.; Piatak, Michael; Mansfield, Keith G.; Li, Wenjun; Miller, Chris J; Lifson, Jeffrey D.; Kozlowski, Pamela A.; Evans, David T.

In: Journal of Virology, Vol. 84, No. 20, 10.2010, p. 10748-10764.

Research output: Contribution to journalArticle

Alpert, MD, Rahmberg, AR, Neidermyer, W, Ng, SK, Carville, A, Camp, JV, Wilson, RL, Piatak, M, Mansfield, KG, Li, W, Miller, CJ, Lifson, JD, Kozlowski, PA & Evans, DT 2010, 'Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge', Journal of Virology, vol. 84, no. 20, pp. 10748-10764. https://doi.org/10.1128/JVI.00945-10
Alpert, Michael D. ; Rahmberg, Andrew R. ; Neidermyer, William ; Ng, Sharon K. ; Carville, Angela ; Camp, Jeremy V. ; Wilson, Robert L. ; Piatak, Michael ; Mansfield, Keith G. ; Li, Wenjun ; Miller, Chris J ; Lifson, Jeffrey D. ; Kozlowski, Pamela A. ; Evans, David T. / Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge. In: Journal of Virology. 2010 ; Vol. 84, No. 20. pp. 10748-10764.
@article{f8fd378cc1514ab5865e6a3893d5f80d,
title = "Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge",
abstract = "Immunization of rhesus macaques with strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection elicits T-cell responses to multiple viral gene products and antibodies capable of neutralizing lab-adapted SIV, but not neutralization-resistant primary isolates of SIV. In an effort to improve upon the antibody responses, we immunized rhesus macaques with three strains of single-cycle SIV (scSIV) that express envelope glycoproteins modified to lack structural features thought to interfere with the development of neutralizing antibodies. These envelope-modified strains of scSIV lacked either five potential N-linked glycosylation sites in gp120, three potential N-linked glycosylation sites in gp41, or 100 amino acids in the V1V2 region of gp120. Three doses consisting of a mixture of the three envelope-modified strains of scSIV were administered on weeks 0, 6, and 12, followed by two booster inoculations with vesicular stomatitis virus (VSV) G trans-complemented scSIV on weeks 18 and 24. Although this immunization regimen did not elicit antibodies capable of detectably neutralizing SIV mac239 or SIVmac251UCD, neutralizing antibody titers to the envelope-modified strains were selectively enhanced. Virus-specific antibodies and T cells were observed in the vaginal mucosa. After 20 weeks of repeated, low-dose vaginal challenge with SIVmac251 UCD, six of eight immunized animals versus six of six na{\"i}ve controls became infected. Although immunization did not significantly reduce the likelihood of acquiring immunodeficiency virus infection, statistically significant reductions in peak and set point viral loads were observed in the immunized animals relative to the na{\"i}ve control animals.",
author = "Alpert, {Michael D.} and Rahmberg, {Andrew R.} and William Neidermyer and Ng, {Sharon K.} and Angela Carville and Camp, {Jeremy V.} and Wilson, {Robert L.} and Michael Piatak and Mansfield, {Keith G.} and Wenjun Li and Miller, {Chris J} and Lifson, {Jeffrey D.} and Kozlowski, {Pamela A.} and Evans, {David T.}",
year = "2010",
month = "10",
doi = "10.1128/JVI.00945-10",
language = "English (US)",
volume = "84",
pages = "10748--10764",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "20",

}

TY - JOUR

T1 - Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge

AU - Alpert, Michael D.

AU - Rahmberg, Andrew R.

AU - Neidermyer, William

AU - Ng, Sharon K.

AU - Carville, Angela

AU - Camp, Jeremy V.

AU - Wilson, Robert L.

AU - Piatak, Michael

AU - Mansfield, Keith G.

AU - Li, Wenjun

AU - Miller, Chris J

AU - Lifson, Jeffrey D.

AU - Kozlowski, Pamela A.

AU - Evans, David T.

PY - 2010/10

Y1 - 2010/10

N2 - Immunization of rhesus macaques with strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection elicits T-cell responses to multiple viral gene products and antibodies capable of neutralizing lab-adapted SIV, but not neutralization-resistant primary isolates of SIV. In an effort to improve upon the antibody responses, we immunized rhesus macaques with three strains of single-cycle SIV (scSIV) that express envelope glycoproteins modified to lack structural features thought to interfere with the development of neutralizing antibodies. These envelope-modified strains of scSIV lacked either five potential N-linked glycosylation sites in gp120, three potential N-linked glycosylation sites in gp41, or 100 amino acids in the V1V2 region of gp120. Three doses consisting of a mixture of the three envelope-modified strains of scSIV were administered on weeks 0, 6, and 12, followed by two booster inoculations with vesicular stomatitis virus (VSV) G trans-complemented scSIV on weeks 18 and 24. Although this immunization regimen did not elicit antibodies capable of detectably neutralizing SIV mac239 or SIVmac251UCD, neutralizing antibody titers to the envelope-modified strains were selectively enhanced. Virus-specific antibodies and T cells were observed in the vaginal mucosa. After 20 weeks of repeated, low-dose vaginal challenge with SIVmac251 UCD, six of eight immunized animals versus six of six naïve controls became infected. Although immunization did not significantly reduce the likelihood of acquiring immunodeficiency virus infection, statistically significant reductions in peak and set point viral loads were observed in the immunized animals relative to the naïve control animals.

AB - Immunization of rhesus macaques with strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection elicits T-cell responses to multiple viral gene products and antibodies capable of neutralizing lab-adapted SIV, but not neutralization-resistant primary isolates of SIV. In an effort to improve upon the antibody responses, we immunized rhesus macaques with three strains of single-cycle SIV (scSIV) that express envelope glycoproteins modified to lack structural features thought to interfere with the development of neutralizing antibodies. These envelope-modified strains of scSIV lacked either five potential N-linked glycosylation sites in gp120, three potential N-linked glycosylation sites in gp41, or 100 amino acids in the V1V2 region of gp120. Three doses consisting of a mixture of the three envelope-modified strains of scSIV were administered on weeks 0, 6, and 12, followed by two booster inoculations with vesicular stomatitis virus (VSV) G trans-complemented scSIV on weeks 18 and 24. Although this immunization regimen did not elicit antibodies capable of detectably neutralizing SIV mac239 or SIVmac251UCD, neutralizing antibody titers to the envelope-modified strains were selectively enhanced. Virus-specific antibodies and T cells were observed in the vaginal mucosa. After 20 weeks of repeated, low-dose vaginal challenge with SIVmac251 UCD, six of eight immunized animals versus six of six naïve controls became infected. Although immunization did not significantly reduce the likelihood of acquiring immunodeficiency virus infection, statistically significant reductions in peak and set point viral loads were observed in the immunized animals relative to the naïve control animals.

UR - http://www.scopus.com/inward/record.url?scp=77957202835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957202835&partnerID=8YFLogxK

U2 - 10.1128/JVI.00945-10

DO - 10.1128/JVI.00945-10

M3 - Article

C2 - 20702641

AN - SCOPUS:77957202835

VL - 84

SP - 10748

EP - 10764

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 20

ER -